{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T15:15:42Z","timestamp":1779117342562,"version":"3.51.4"},"reference-count":33,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2007,3,1]],"date-time":"2007-03-01T00:00:00Z","timestamp":1172707200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Sleep Medicine"],"published-print":{"date-parts":[[2007,3]]},"DOI":"10.1016\/j.sleep.2006.05.018","type":"journal-article","created":{"date-parts":[[2007,1,19]],"date-time":"2007-01-19T12:19:16Z","timestamp":1169209156000},"page":"119-127","source":"Crossref","is-referenced-by-count":16,"title":["Efficacy and tolerability of sumanirole in restless legs syndrome: A phase II, randomized, double-blind, placebo-controlled, dose\u2013response study"],"prefix":"10.1016","volume":"8","author":[{"given":"Diego","family":"Garcia-Borreguero","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Winkelman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alieu","family":"Adams","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amanda","family":"Ellis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Morris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janice","family":"Lamb","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gary","family":"Layton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Versavel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.sleep.2006.05.018_bib1","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.sleep.2004.01.004","article-title":"Epidemiology and clinical findings of restless legs syndrome","volume":"5","author":"Zucconi","year":"2004","journal-title":"Sleep Med"},{"key":"10.1016\/j.sleep.2006.05.018_bib2","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.sleep.2004.03.006","article-title":"Impact, diagnosis and treatment of restless legs syndrome (RLS) in a primary care population: the REST (RLS epidemiology, symptoms, and treatment) primary care study","volume":"5","author":"Hening","year":"2004","journal-title":"Sleep Med"},{"key":"10.1016\/j.sleep.2006.05.018_bib3","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1345\/aph.10271","article-title":"Newer dopamine agonists in the treatment of restless legs syndrome","volume":"35","author":"Weimerskirch","year":"2001","journal-title":"Ann Pharmacother"},{"issue":"1","key":"10.1016\/j.sleep.2006.05.018_bib4","doi-asserted-by":"crossref","first-page":"27","DOI":"10.2165\/00023210-200418010-00003","article-title":"Role of dopamine receptor agonists in the treatment of restless legs syndrome","volume":"18","author":"Happe","year":"2004","journal-title":"CNS Drugs"},{"issue":"1","key":"10.1016\/j.sleep.2006.05.018_bib5","first-page":"92","article-title":"Therapy with Ropinirole; efficacy and tolerability in RLS 1 Study Group. Ropinirole in the treatment of restless legs syndrome: results from the TREAT RLS 1 study, a 12 week, randomised, placebo controlled study in 10 European countries","volume":"75","author":"Trenkwalder","year":"2004","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.sleep.2006.05.018_bib6","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1212\/WNL.54.5.1064","article-title":"Prevalence and risk factors of RLS in an elderly population. The MEMO study","volume":"54","author":"Rothdach","year":"2000","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.sleep.2006.05.018_bib7","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/S1389-9457(03)00010-8","article-title":"Restless legs syndrome: diagnostic criteria, special considerations and epidemiology. A report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institute of Health","volume":"4","author":"Allen","year":"2003","journal-title":"Sleep Med"},{"key":"10.1016\/j.sleep.2006.05.018_bib8","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1007\/PL00007859","article-title":"SPECT imaging of striatal pre- and postsynaptic dopaminergic status in restless legs syndrome with periodic leg movements in sleep","volume":"249","author":"Michaud","year":"2002","journal-title":"J Neurol"},{"key":"10.1016\/j.sleep.2006.05.018_bib9","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1212\/WNL.54.2.502","article-title":"An F DOPA PET study in patients with periodic limb movement disorder","volume":"54","author":"Ruottinen","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/j.sleep.2006.05.018_bib10","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1212\/WNL.52.5.932","article-title":"Striatal dopaminergic function in restless legs syndrome: 18F-dopa and 11C-raclopride PET studies","volume":"52","author":"Turjanski","year":"1999","journal-title":"Neurology"},{"key":"10.1016\/j.sleep.2006.05.018_bib11","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.sleep.2004.05.006","article-title":"Restless legs syndrome: clinical experience with long-term treatment","volume":"5","author":"Clavadetscher","year":"2004","journal-title":"Sleep Med"},{"issue":"1","key":"10.1016\/j.sleep.2006.05.018_bib12","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1002\/mds.870120111","article-title":"Clinical, polysomnographic, and genetic characteristics of restless legs syndrome: a study of 133 patients diagnosed with new standard criteria","volume":"12","author":"Montplaisir","year":"1997","journal-title":"Mov Disord"},{"issue":"3","key":"10.1016\/j.sleep.2006.05.018_bib13","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S1389-9457(00)00080-0","article-title":"Validation of the Johns Hopkins restless legs severity scale","volume":"2","author":"Allen","year":"2001","journal-title":"Sleep Med"},{"issue":"2","key":"10.1016\/j.sleep.2006.05.018_bib14","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1159\/000062996","article-title":"Sleep laboratory diagnosis of restless legs syndrome","volume":"48","author":"Michaud","year":"2002","journal-title":"Eur Neurol"},{"issue":"8504","key":"10.1016\/j.sleep.2006.05.018_bib15","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/S0140-6736(86)92135-5","article-title":"Levodopa in restless legs","volume":"2","author":"von Scheele","year":"1986","journal-title":"Lancet"},{"key":"10.1016\/j.sleep.2006.05.018_bib16","doi-asserted-by":"crossref","unstructured":"The PEARLS Study Group (C. Trenkwalder-Group Organizer and Correspondent), efficacy of pergolide in treatment of restless legs syndrome: the PEARLS Study. Neurology 2004;62(8):1391\u201397.","DOI":"10.1212\/01.WNL.0000124465.20878.84"},{"issue":"7","key":"10.1016\/j.sleep.2006.05.018_bib17","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1093\/sleep\/26.7.819","article-title":"Pramipexole in the management of restless legs syndrome: an extended study","volume":"26","author":"Silber","year":"2003","journal-title":"Sleep"},{"issue":"4","key":"10.1016\/j.sleep.2006.05.018_bib18","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1093\/sleep\/27.4.674","article-title":"Long-term safety and efficacy of cabergoline for the treatment of idiopathic restless legs syndrome: results from an open-label 6-month clinical trial","volume":"27","author":"Benes","year":"2004","journal-title":"Sleep"},{"issue":"12","key":"10.1016\/j.sleep.2006.05.018_bib19","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1002\/mds.20257","article-title":"Ropinirole is effective in the treatment of restless legs syndrome. TREAT RLS 2: a 12-week, double-blind, randomized, parallel-group, placebo-controlled study","volume":"19","author":"Walters","year":"2004","journal-title":"Mov Disord"},{"issue":"10","key":"10.1016\/j.sleep.2006.05.018_bib20","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1517\/14656566.4.10.1727","article-title":"Current treatment options for restless legs syndrome","volume":"4","author":"Wetter","year":"2003","journal-title":"Expert Opin Pharmacother"},{"issue":"3","key":"10.1016\/j.sleep.2006.05.018_bib21","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/sleep\/19.3.205","article-title":"Augmentation of the restless legs syndrome with carbidopa\/levodopa","volume":"19","author":"Allen","year":"1996","journal-title":"Sleep"},{"key":"10.1016\/j.sleep.2006.05.018_bib22","doi-asserted-by":"crossref","first-page":"916","DOI":"10.4065\/79.7.916","article-title":"An algorithm for the management of restless legs syndrome","volume":"79","author":"Silber","year":"2004","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.sleep.2006.05.018_bib23","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1136\/jnnp.50.12.1706","article-title":"Pleuropulmonary and retroperitoneal fibrosis associated with bromocriptine treatment","volume":"50","author":"Ward","year":"1987","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"3","key":"10.1016\/j.sleep.2006.05.018_bib24","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1097\/00002826-200305000-00001","article-title":"Fibrosis associated with dopamine agonist therapy in Parkinson\u2019s disease","volume":"26","author":"Muller","year":"2003","journal-title":"Clin Neuropharmacol"},{"issue":"8","key":"10.1016\/j.sleep.2006.05.018_bib25","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1001\/archneur.62.8.1290","article-title":"Pleuropulmonary fibrosis after long-term treatment with the dopamine agonist pergolide for Parkinson disease","volume":"62","author":"Tintner","year":"2005","journal-title":"Arch Neurol"},{"key":"10.1016\/j.sleep.2006.05.018_bib26","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1021\/jm960360q","article-title":"Synthesis and biological activities of (R)-5,6-dihydro-N,N-dimethyl-4H-imidazo[4,5,1-ij]quinolin-5-amine and its metabolites","volume":"40","author":"Heier","year":"1997","journal-title":"J Med Chem"},{"key":"10.1016\/j.sleep.2006.05.018_bib27","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1124\/jpet.105.084202","article-title":"Sumanirole, a highly dopamine D2-selective receptor agonist: in vitro and in vivo pharmacological characterization and efficacy in animal models of Parkinson\u2019s disease","volume":"314","author":"McCall","year":"2005","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.sleep.2006.05.018_bib28","doi-asserted-by":"crossref","unstructured":"The International Restless Legs Syndrome Study Group (Arthur S. Walters MD-Group Organizer and Correspondent), Validation of the International Restless Legs Syndrome Study Group Rating Scale for Restless Legs Syndrome. Sleep Med 2003;4:121\u2013132.","DOI":"10.1016\/S1389-9457(02)00258-7"},{"key":"10.1016\/j.sleep.2006.05.018_bib29","series-title":"A manual of standardized terminology, techniques, and scoring systems for sleep stages of human subjects","author":"Rechtschaffen","year":"1968"},{"key":"10.1016\/j.sleep.2006.05.018_bib30","series-title":"Sleeping and waking disorders: indications and techniques","first-page":"265","article-title":"Periodic movements in sleep (nocturnal myoclonus) and restless legs syndrome","author":"Coleman","year":"1982"},{"key":"10.1016\/j.sleep.2006.05.018_bib31","doi-asserted-by":"crossref","unstructured":"Atlas Task Force of the American Sleep Disorders Association. Recording and scoring of leg movements. Sleep 1993;16:748\u201359.","DOI":"10.1093\/sleep\/16.8.748"},{"issue":"5","key":"10.1016\/j.sleep.2006.05.018_bib32","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1093\/sleep\/27.5.907","article-title":"Ropinirole decreases periodic leg movements and improves sleep parameters in patients with restless legs syndrome","volume":"27","author":"Allen","year":"2004","journal-title":"Sleep"},{"issue":"6415","key":"10.1016\/j.sleep.2006.05.018_bib33","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1136\/bmj.288.6415.444","article-title":"Treatment of the restless legs syndrome with carbamazepine: a double blind study","volume":"288","author":"Telstad","year":"1984","journal-title":"Br Med J (Clin Res Ed)"}],"container-title":["Sleep Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1389945706001924?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1389945706001924?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,4,23]],"date-time":"2019-04-23T21:27:46Z","timestamp":1556054866000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1389945706001924"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,3]]},"references-count":33,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2007,3]]}},"alternative-id":["S1389945706001924"],"URL":"https:\/\/doi.org\/10.1016\/j.sleep.2006.05.018","relation":{},"ISSN":["1389-9457"],"issn-type":[{"value":"1389-9457","type":"print"}],"subject":[],"published":{"date-parts":[[2007,3]]}}}